Equities

Shanghai Aladdin Biochemical Technology Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Shanghai Aladdin Biochemical Technology Co Ltd

Actions
Basic MaterialsChemicals
  • Price (CNY)15.86
  • Today's Change0.01 / 0.06%
  • Shares traded5.65m
  • 1 Year change+25.79%
  • Beta1.4049
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Shanghai Aladdin Biochemical Technology Co Ltd is a China-based company mainly engaged in the research and development, production and sales of scientific research reagents. The Company's businesses cover the four major areas of high-end chemistry, life sciences, analytical chromatography and materials science, and experimental consumables. The Company's products are used in universities, scientific research institutes, biomedicine, new materials, new energy, energy conservation and environmental protection, aerospace and other fields. The Company independently builds Aladdin brand scientific research reagents and Silicon Valley brand experimental consumables, mainly relying on its own e-commerce platform www.aladdin-e.com to achieve online sales. The Company mainly conducts its businesses in the China market.

  • Revenue in CNY (TTM)599.98m
  • Net income in CNY83.95m
  • Incorporated2009
  • Employees652.00
  • Location
    Shanghai Aladdin Biochemical Technology Co Ltd16F, South Tower, No. 36Xinjinqiao Road, Pudong New AreaSHANGHAI 201206ChinaCHN
  • Phone+86 2 150560989
  • Fax+86 2 150323701
  • Websitehttps://www.aladdin-e.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
688179:SHH since
announced
Transaction
value
CASMART Holdings Co LtdDeal completed09 Aug 202509 Aug 2025Deal completed5.73%36.33m
Data delayed at least 15 minutes, as of Feb 13 2026.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Xinjiang Bai Hua Cun Pharma Tech Co Ltd393.73m50.20m3.57bn731.0071.074.50--9.070.13070.13071.022.060.35031.941.88538,619.704.47-4.606.16-6.3851.8224.7512.75-16.331.81--0.00--4.468.04219.753.82-0.975--
Qingdao Vland Biotech INC1.39bn83.57m3.96bn1.57k47.542.23--2.850.3290.3295.507.010.45853.893.65--3.764.846.116.9444.1945.528.209.540.877--0.264832.3510.169.30-22.39-4.23-2.71-6.89
Hinova Pharmaceuticals Inc23.61m-144.57m4.47bn173.00--4.06--189.15-1.46-1.460.238411.120.01712.375.59136,467.70-10.45-26.09-11.68-29.7495.50---612.36-78,863.606.90--0.0883-----38.6732.18--139.77--
Shanghai Aladdin Biochemical Tech Co Ltd599.98m83.95m5.28bn652.0063.824.95--8.790.24850.24851.783.210.27850.42184.55920,216.305.047.816.908.6062.2160.6118.0924.951.539.150.354148.3332.4420.5515.079.1741.61--
Hangzhou Alltest Biotech Co Ltd881.63m294.76m5.41bn969.0018.331.39--6.143.723.7211.1249.210.20982.386.39909,839.107.0219.187.5721.6655.0057.7933.4738.828.34--0.009335.1414.8329.1367.5030.9971.01--
Bide Pharmatech Co Ltd1.27bn153.31m5.43bn738.0033.982.71--4.271.761.7614.4922.030.51670.88045.251,720,520.006.247.027.528.2943.3042.1612.0713.132.78--0.105548.730.929834.697.17--80.65--
Shouyao Holdings Co Ltd2.14m-206.73m5.78bn178.00--8.83--2,697.32-1.39-1.390.01444.400.00250.03660.262512,033.88-23.67-32.53-27.20-36.2595.7499.43-9,651.03-3,370.016.42--0.0044---24.61-19.34-14.21--49.71--
Jiangsu Yahong Meditech Co Ltd279.02m-362.17m6.84bn391.00--3.86--24.52-0.642-0.6420.49333.100.12511.164.19713,603.90-16.84-14.30-19.15-15.0172.2273.78-134.65-703.804.96--0.1545--1,365.55--4.09--50.48--
GemPharmatech Co Ltd752.70m121.51m6.98bn1.58k56.613.17--9.270.30070.30071.865.370.28074.511.88476,993.404.537.695.428.9661.8468.1716.1425.583.17--0.129521.9410.3928.94-30.8925.8820.02--
Beijing Sun-Novo Pharma Research Co Ltd1.02bn133.01m7.46bn1.36k54.876.42--7.341.211.219.2310.380.474535.481.28653,956.406.0411.3910.4918.8248.6053.3112.7219.661.789.970.335511.2915.7035.80-3.9830.213.50--
Data as of Feb 13 2026. Currency figures normalised to Shanghai Aladdin Biochemical Technology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

5.06%Per cent of shares held by top holders
HolderShares% Held
Zhong Ou Asset Management Co., Ltdas of 30 Jun 20259.57m3.45%
GF Fund Management Co., Ltd.as of 30 Jun 2025857.39k0.31%
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 30 Jun 2025545.63k0.20%
CIB Fund Management Co., Ltd.as of 30 Jun 2025544.30k0.20%
China Merchants Fund Management Co., Ltd.as of 30 Jun 2025535.27k0.19%
China Fund Management Co., Ltd.as of 30 Jun 2025529.13k0.19%
JX Asset Management Co.,Ltdas of 30 Jun 2025441.14k0.16%
Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2025404.11k0.15%
Guotai Asset Management Co., Ltd.as of 30 Jun 2025302.69k0.11%
UBS SDIC Fund Management Co., Ltd.as of 30 Jun 2025293.15k0.11%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.